U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 – Sarepta Therapeutics
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has received a significant designation from the U.S. Food and Drug Adm…
Leggi tutto